While tumor‐suppressive consequences were observed in most of the primary SMAD4 wild‐type PDTs, metastatic lines were less sensitive, and the presence of an atypical KRASQ22K mutation rendered PDT1 insensitive to the inhibitory effects of TGF‐β1. This evidence concerns the gene SMAD4 and neoplasm.